[u'-----BEGIN PRIVACY-ENHANCED MESSAGE-----\nProc-Type: 2001,MIC-CLEAR\nOriginator-Name: webmaster@www.sec.gov\nOriginator-Key-Asymmetric:\n MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen\n TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB\nMIC-Info: RSA-MD5,RSA,\n D/80vzd1PfACZIlAXu+EHlVb4ZlZ41himayt+sLpW5x8p8FTxVV0s9ImaouhgIaX\n 985QBDPEp2O0imSajbvanQ==\n\n', u'0001193125-04-162299.txt : 20040927\n', u'0001193125-04-162299.hdr.sgml : 20040927\n', u'20040927161318\nACCESSION NUMBER:\t\t0001193125-04-162299\nCONFORMED SUBMISSION TYPE:\t8-K\nPUBLIC DOCUMENT COUNT:\t\t3\nCONFORMED PERIOD OF REPORT:\t20040927\nITEM INFORMATION:\t\tResults of Operations and Financial Condition\nITEM INFORMATION:\t\tFinancial Statements and Exhibits\nFILED AS OF DATE:\t\t20040927\nDATE AS OF CHANGE:\t\t20040927\n\nFILER:\n\n\tCOMPANY DATA:\t\n\t\tCOMPANY CONFORMED NAME:\t\t\tCORTEX PHARMACEUTICALS INC/DE/\n\t\tCENTRAL INDEX KEY:\t\t\t0000849636\n\t\tSTANDARD INDUSTRIAL CLASSIFICATION:\tPHARMACEUTICAL PREPARATIONS [2834]\n\t\tIRS NUMBER:\t\t\t\t330303583\n\t\tSTATE OF INCORPORATION:\t\t\tDE\n\t\tFISCAL YEAR END:\t\t\t0630\n\n\tFILING VALUES:\n\t\tFORM TYPE:\t\t8-K\n\t\tSEC ACT:\t\t1934 Act\n\t\tSEC FILE NUMBER:\t001-16467\n\t\tFILM NUMBER:\t\t041047415\n\n\tBUSINESS ADDRESS:\t\n\t\tSTREET 1:\t\t15241 BARRANCA PKWY\n\t\tCITY:\t\t\tIRVINE\n\t\tSTATE:\t\t\tCA\n\t\tZIP:\t\t\t92718\n\t\tBUSINESS PHONE:\t\t7147273157\n\n\tMAIL ADDRESS:\t\n\t\tSTREET 1:\t\t15241 BARRANCA PARKWAY\n\t\tCITY:\t\t\tIRVINE\n\t\tSTATE:\t\t\tCA\n\t\tZIP:\t\t\t92718\n', u'\n', u'\n', u'8-K\n', u'1\n', u'd8k.htm\n', u'FORM 8-K\n', u'\n', u'Form 8-K', u'\n', u'UNITED STATES ', u' ', u'SECURITIES AND EXCHANGE COMMISSION ', u' ', u'Washington, D.C. 20549 ', u' ', u'\xa0', u' ', u'\xa0', u' ', u'\xa0', u' ', u'Form 8-K ', u' ', u'\xa0', u' ', u'Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 ', u' ', u'\xa0', u' ', u'\xa0', u' ', u'\xa0', u' ', u'Date of Report (Date of earliest event reported) ', u' ', u'\xa0', u' ', u'September 27, 2004 ', u' ', u'\xa0', u' ', u'\xa0', u' ', u'CORTEX PHARMACEUTICALS, INC. ', u' ', u'(Exact name of registrant as specified in its charter) ', u' ', u'\xa0', u' ', u'\xa0', u' ', u'\xa0', u'\n', u'\n', u'\n', u'\n', u'\n', u'\n', u'\n', u'\n', u'\n', u' ', u'Delaware', u'\n', u'\xa0', u'\n', u' ', u'0-17951', u'\n', u'\xa0', u'\n', u' ', u'33-0303583', u'\n', u'\n', u' ', u'(State or other jurisdiction of', u' ', u'incorporation)', u'\n', u'\xa0', u'\n', u'(Commission File Number)', u'\n', u'\xa0', u'\n', u'(I.R.S Employer Identification No.)', u'\n', u' ', u'\xa0', u'\n', u'\n', u'\n', u'\n', u'\n', u'\n', u'\n', u' ', u'15241 Barranca Parkway', u' ', u'Irvine, California', u'\n', u'\xa0', u'\n', u' ', u'92618', u'\n', u'\n', u'(Address of principal executive offices)', u'\n', u'\xa0', u'\n', u'(Zip Code)', u'\n', u' ', u'\xa0', u' ', u'\xa0', u' ', u'\xa0', u' ', u'Registrant\x92s telephone number, including area code: (949) 727-3157\n', u' ', u'\xa0', u' ', u'\xa0', u' ', u'\xa0', u' ', u'N/A ', u' ', u'(Former name or former address, if changed since last report.) ', u' ', u'\xa0', u' ', u'\xa0', u' ', u'\xa0', u' ', u'Check the\nappropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ', u' ', u'\xa0', u'\n', u'\n', u'\n', u'\xa8', u'\n', u'Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ', u' ', u'\xa0', u'\n', u'\n', u'\n', u'\xa8', u'\n', u'Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ', u' ', u'\xa0', u'\n', u'\n', u'\n', u'\xa8', u'\n', u'Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ', u' ', u'\xa0', u'\n', u'\n', u'\n', u'\xa8', u'\n', u'Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) ', u'\n', u'\n', u'\n', u'Item 2.02. \xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0Results of Operations and Financial Condition.\n', u' ', u'\xa0', u' ', u'On September 27, 2004, Cortex Pharmaceuticals, Inc.\nissued a press release to report its financial results. The press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference. ', u' ', u'\xa0', u' ', u'All of the foregoing information, including Exhibit 99.1, is being furnished under Item 2.02 and shall not be deemed \x93filed\x94 for purposes of\nSection 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liability of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, except as shall be\nexpressly set forth by specific reference in such a filing. ', u' ', u'\xa0', u' ', u'Item 9.01.\n\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0Financial Statements and Exhibits. ', u' ', u'\xa0', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'(a)', u'\n', u'Financial Statements of Businesses Acquired: None. ', u' ', u'\xa0', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'(b)', u'\n', u'Pro Forma Financial Information: None. ', u' ', u'\xa0', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'(c)', u'\n', u'Exhibits. ', u' ', u'\xa0', u'\n', u'\n', u'\n', u'\n', u'\n', u'\n', u'\n', u'Exhibit', u'Number', u'\n', u'\xa0', u'\n', u'\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\n\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0Description', u'\n', u'\n', u'\n', u'\n', u'\n', u'99.1', u'\n', u'\xa0', u'\n', u'Press release of Cortex Pharmaceuticals, Inc. dated September 27, 2004.', u'\n', u'\n', u'\n', u'\n', u'SIGNATURES ', u' ', u'\xa0', u' ', u'Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the\nundersigned hereunto duly authorized. ', u' ', u'\xa0', u' ', u'\xa0', u'\n', u'\n', u'\n', u'\n', u'\n', u'\n', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u' ', u'CORTEX PHARMACEUTICALS, INC.', u'\n', u'\n', u'\n', u'\n', u'\n', u'\n', u' ', u'Date: September 27, 2004', u'\n', u'\xa0', u'\n', u' ', u'By:', u'\n', u'\xa0', u'\n', u' ', u'\xa0\xa0\xa0\xa0/s/ Maria S. Messinger', u'\n', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u' ', u'Maria S. Messinger', u'\n', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u' ', u'Vice President, Chief Financial Officer', u' ', u'and Corporate Secretary', u'\n', u'\n', u'\n', u'\n', u'EXHIBIT INDEX ', u' ', u'\xa0', u'\n', u'\n', u'\n', u'\n', u'\n', u'\n', u'\n', u'\n', u'\n', u'Exhibit', u'Number', u'\n', u'\xa0', u'\n', u'Description', u'\n', u'\xa0', u'\n', u' ', u'Sequential', u' ', u'Page No.', u'\n', u'\n', u'\n', u'\n', u'\n', u'\n', u'\n', u'\n', u'99.1', u'\n', u'\xa0', u'\n', u'Press release of Cortex Pharmaceuticals, Inc. dated September 27, 2004.', u'\n', u'\xa0', u'\n', u'5', u'\n', u'\n', u'\n', u'\n', u'\n', u'EX-99.1\n', u'2\n', u'dex991.htm\n', u'PRESS RELEASE\n', u'\n', u'Press release', u'\n', u'Exhibit 99.1 ', u' ', u'\xa0', u' ', u'\n', u' ', u' ', u'\xa0', u' ', u'Press Release ', u' ', u'\xa0', u'\n', u'\n', u'\n', u'\n', u'\n', u'\n', u'\n', u' ', u'Company Contact:', u'\n', u'\xa0', u'\n', u' ', u'Investor Contact:', u'\n', u'\n', u' ', u'Roger G. Stoll, Ph.D.', u'\n', u'\xa0', u'\n', u' ', u'Jane Lin/ Dian Griesel, Ph.D.', u'\n', u'\n', u' ', u'Chairman, President and CEO', u'\n', u'\xa0', u'\n', u' ', u'The Investor Relations Group', u'\n', u'\n', u' ', u'Cortex Pharmaceuticals, Inc.', u'\n', u'\xa0', u'\n', u' ', u'212.825.3210', u'\n', u'\n', u' ', u'949.727.3157', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u' ', u'\xa0', u' ', u'\xa0', u' ', u'Cortex Reports Fourth Quarter and Fiscal 2004 Results ', u' ', u'\xa0', u' ', u'IRVINE, CA', u' (September 27, 2004) \x97 Cortex Pharmaceuticals, Inc. (AMEX: COR) reported a net loss of $1,314,000 ($0.05 per share) for the quarter\nended June 30, 2004, compared with a net loss of $85,000 ($0.01 per share) for the corresponding prior year period, with the difference representing development expenses for the A', u'MPAKINE', u'\xae', u' compound, CX717. ', u' ', u'\xa0', u' ', u'For the fiscal year ended June 30, 2004, Cortex reported a net loss of $5,994,000 ($0.26 per share), compared to a net loss\nof $1,175,000 ($0.07 per share) for the corresponding prior year period. Research and development expenses for the year ended June 30, 2004 increased to $6,116,000 compared to $3,724,000 for the prior year period, with the increase reflecting the\ncosts for CX717 preclinical toxicology and Phase I clinical testing. General and administrative expenses for the year ended June 30, 2004 decreased to $2,291,000 from $2,480,000 for the prior year period. Increased expenses for fiscal year 2004 also\nreflected non-cash charges, including $3,603,000 primarily related to warrants issued in Cortex\x92s August 2003 private placement. The non-cash charges had no impact on Cortex\x92s working capital or its liquidity. ', u' ', u'\xa0', u' ', u'Revenues for the year ended June 30, 2004 of $6,973,000 compared to\n$5,232,000 for the corresponding prior year period, with fiscal 2004 revenues including the $2,000,000 milestone payment received from Organon, as previously reported. Organon paid the milestone in order to retain its rights to Cortex\x92s\nA', u'MPAKINE', u' technology in the field of depression. ', u' ', u'\xa0', u' ', u'During the year ended June 30, 2004 Cortex significantly improved its balance sheet, with net proceeds of approximately $22 million from two private placements of its common stock. These proceeds allowed the Company to accelerate its\ndevelopment plans for CX717, as well as other A', u'MPAKINE', u' compounds. Cortex\x92s working capital increased to $20,568,000 as of June 30, 2004 compared to a working capital deficit of $1,504,000 as of June 30, 2003. ', u'\n', u'\n', u'\n', u'Cortex Pharmaceuticals, Inc. ', u' ', u'\xa0', u' ', u'Cortex, located in Irvine, California, is a neuroscience company focused on novel drug therapies for neurological and psychiatric disorders.\nThe Company is pioneering a class of proprietary pharmaceuticals called A', u'MPAKINE', u' compounds, which act to increase the strength of signals at connections between brain cells. The loss of these connections is thought to be responsible\nfor memory and behavior problems in Alzheimer\x92s disease. Many psychiatric diseases, including schizophrenia, occur as a result of imbalances in the brain\x92s neurotransmitter system. These imbalances may be improved by using the\nA', u'MPAKINE', u' technology. Cortex has alliances with N.V. Organon for the treatment of schizophrenia and depression and with Les Laboratories Servier for the development of A', u'MPAKINE', u' compounds to treat the neurodegenerative\neffects associated with aging and disease, including Mild Cognitive Impairment, Alzheimer\x92s disease and anxiety disorders. Cortex is currently developing CX717, a second generation A', u'MPAKINE', u' compound, for Alzheimer\x92s disease\nand Attention Deficit Hyperactivity Disorder (\x93ADHD\x94).', u' ', u' ', u'\xa0', u' ', u'Forward-Looking Statement ', u' ', u'\xa0', u' ', u'Note \x97 This press release\ncontains forward-looking statements concerning the Company\x92s research and development activities, clinical trials and business development plans. Actual results may differ materially, depending on a number of risk factors, including the risks\nthat the agreements with Organon and Servier will not result in any commercial products or that any additional milestone payments will be earned by the Company; that the Company may be unable to arrive at additional corporate partnerships with other\npharmaceutical companies on acceptable terms and therefore be required to independently fund clinical development of A', u'MPAKINE', u' compounds through the sale of additional equity securities or otherwise; that the Company\x92s proposed\nproducts may at any time be found to be unsafe or ineffective for any or all of their proposed indications; that competitors may challenge or design around the Company\x92s patents or develop competing technologies; and that clinical studies may\nat any point be suspended or take substantially longer than anticipated to complete. As discussed in the Company\x92s Securities and Exchange Commission filings, the Company\x92s proposed products will require additional research, lengthy and\ncostly clinical testing and regulatory approval. A', u'MPAKINE', u' compounds are investigational drugs and have not been approved for the treatment of any disease. ', u' ', u'\xa0', u' ', u'\xa0', u' ', u'\xa0', u' ', u'(tables follow) ', u'\n', u'\n', u'\n', u'Cortex Pharmaceuticals, Inc. ', u' ', u'Condensed Statements of Operations ', u' ', u'(in thousands, except per share data)\n', u' ', u'(Unaudited) ', u' ', u'\xa0', u'\n', u'\n', u'\n', u'\n', u'\n', u'\n', u'\n', u'\n', u'\n', u'\n', u'\n', u'\n', u'\n', u'\n', u'\n', u'\n', u'\n', u'\n', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\xa0\xa0', u'\n', u'Three\xa0months\xa0ended', u'June 30,', u'\n', u'\xa0', u'\n', u'\xa0\xa0', u'\n', u' ', u'Year ended', u' ', u'June 30,', u'\n', u'\xa0', u'\n', u'\n', u'\xa0', u'\n', u'\xa0\xa0', u'\n', u'2004', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'2003', u'\n', u'\xa0', u'\n', u'\xa0\xa0', u'\n', u'2004', u'\n', u'\xa0', u'\n', u'\xa0\xa0', u'\n', u'2003', u'\n', u'\xa0', u'\n', u'\n', u' ', u'Revenues', u'\n', u'\xa0\xa0', u'\n', u'$', u'\n', u'1,214', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'$', u'\n', u'1,349', u'\n', u'\xa0', u'\n', u'\xa0\xa0', u'\n', u'$', u'\n', u'6,973', u'\n', u'\xa0', u'\n', u'\xa0\xa0', u'\n', u'$', u'\n', u'5,232', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\n', u'\n', u'\n', u'\n', u'\n', u' ', u'Operating expenses:', u'\n', u'\xa0\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\n', u' ', u'Research and development', u'\n', u'\xa0\xa0', u'\n', u'\xa0', u'\n', u'2,083', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'816', u'\n', u'\xa0', u'\n', u'\xa0\xa0', u'\n', u'\xa0', u'\n', u'6,116', u'\n', u'\xa0', u'\n', u'\xa0\xa0', u'\n', u'\xa0', u'\n', u'3,724', u'\n', u'\xa0', u'\n', u'\n', u' ', u'General and administrative', u'\n', u'\xa0\xa0', u'\n', u'\xa0', u'\n', u'514', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'537', u'\n', u'\xa0', u'\n', u'\xa0\xa0', u'\n', u'\xa0', u'\n', u'2,291', u'\n', u'\xa0', u'\n', u'\xa0\xa0', u'\n', u'\xa0', u'\n', u'2,480', u'\n', u'\xa0', u'\n', u'\n', u' ', u'Non-cash stock compensation charges', u'\n', u'\xa0\xa0', u'\n', u'\xa0', u'\n', u'35', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'82', u'\n', u'\xa0', u'\n', u'\xa0\xa0', u'\n', u'\xa0', u'\n', u'1,106', u'\n', u'\xa0', u'\n', u'\xa0\xa0', u'\n', u'\xa0', u'\n', u'217', u'\n', u'\xa0', u'\n', u'\n', u'\xa0', u'\n', u'\xa0\xa0', u'\n', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\n', u'\xa0\xa0', u'\n', u'\n', u'\n', u'\n', u'\xa0\xa0', u'\n', u'\n', u'\n', u'\n', u'\n', u' ', u'Total operating expenses', u'\n', u'\xa0\xa0', u'\n', u'\xa0', u'\n', u'2,632', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'1,435', u'\n', u'\xa0', u'\n', u'\xa0\xa0', u'\n', u'\xa0', u'\n', u'9,513', u'\n', u'\xa0', u'\n', u'\xa0\xa0', u'\n', u'\xa0', u'\n', u'6,421', u'\n', u'\xa0', u'\n', u'\n', u'\xa0', u'\n', u'\xa0\xa0', u'\n', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\n', u'\xa0\xa0', u'\n', u'\n', u'\n', u'\n', u'\xa0\xa0', u'\n', u'\n', u'\n', u'\n', u'\n', u' ', u'Loss from operations', u'\n', u'\xa0\xa0', u'\n', u'\xa0', u'\n', u'(1,418', u'\n', u')', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'(86', u'\n', u')', u'\n', u'\xa0\xa0', u'\n', u'\xa0', u'\n', u'(2,540', u'\n', u')', u'\n', u'\xa0\xa0', u'\n', u'\xa0', u'\n', u'(1,189', u'\n', u')', u'\n', u'\n', u' ', u'Interest income, net', u'\n', u'\xa0\xa0', u'\n', u'\xa0', u'\n', u'104', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'1', u'\n', u'\xa0', u'\n', u'\xa0\xa0', u'\n', u'\xa0', u'\n', u'149', u'\n', u'\xa0', u'\n', u'\xa0\xa0', u'\n', u'\xa0', u'\n', u'14', u'\n', u'\xa0', u'\n', u'\n', u' ', u'Increase in fair value of common stock warrants', u'\n', u'\xa0\xa0', u'\n', u'\xa0', u'\n', u'\x97', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\x97', u'\n', u'\xa0', u'\n', u'\xa0\xa0', u'\n', u'\xa0', u'\n', u'(3,603', u'\n', u')', u'\n', u'\xa0\xa0', u'\n', u'\xa0', u'\n', u'\x97', u'\n', u'\xa0', u'\n', u'\n', u'\xa0', u'\n', u'\xa0\xa0', u'\n', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\n', u'\xa0\xa0', u'\n', u'\n', u'\n', u'\n', u'\xa0\xa0', u'\n', u'\n', u'\n', u'\n', u'\n', u' ', u'Net loss applicable to common stock', u'\n', u'\xa0\xa0', u'\n', u'$', u'\n', u'(1,314', u'\n', u')', u'\n', u'\xa0', u'\n', u'$', u'\n', u'(85', u'\n', u')', u'\n', u'\xa0\xa0', u'\n', u'$', u'\n', u'(5,994', u'\n', u')', u'\n', u'\xa0\xa0', u'\n', u'$', u'\n', u'(1,175', u'\n', u')', u'\n', u'\n', u'\xa0', u'\n', u'\xa0\xa0', u'\n', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\n', u'\xa0\xa0', u'\n', u'\n', u'\n', u'\n', u'\xa0\xa0', u'\n', u'\n', u'\n', u'\n', u'\n', u' ', u'Loss per share:', u'\n', u'\xa0\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\n', u' ', u'Basic and diluted', u'\n', u'\xa0\xa0', u'\n', u'$', u'\n', u'(0.05', u'\n', u')', u'\n', u'\xa0', u'\n', u'$', u'\n', u'(0.01', u'\n', u')', u'\n', u'\xa0\xa0', u'\n', u'$', u'\n', u'(0.26', u'\n', u')', u'\n', u'\xa0\xa0', u'\n', u'$', u'\n', u'(0.07', u'\n', u')', u'\n', u'\n', u'\n', u'\n', u'\n', u'\n', u'\n', u'\n', u' ', u'Shares used in basic and diluted calculation', u'\n', u'\xa0\xa0', u'\n', u'\xa0', u'\n', u'28,297', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'16,910', u'\n', u'\xa0', u'\n', u'\xa0\xa0', u'\n', u'\xa0', u'\n', u'23,182', u'\n', u'\xa0', u'\n', u'\xa0\xa0', u'\n', u'\xa0', u'\n', u'16,868', u'\n', u'\xa0', u'\n', u' ', u'\xa0', u' ', u'\xa0', u' ', u'Cortex Pharmaceuticals, Inc. ', u' ', u'Condensed Balance Sheets ', u' ', u'(in thousands) ', u' ', u'\xa0', u'\n', u'\n', u'\n', u'\n', u'\n', u'\n', u'\n', u'\n', u'\n', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\xa0\xa0', u'\n', u'June\xa030,', u'2004', u'\n', u'\xa0\xa0', u'\n', u'June\xa030,', u'2003', u'\n', u'\xa0', u'\n', u'\n', u' ', u'Assets:', u'\n', u'\xa0\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\n', u' ', u'Cash and cash equivalents', u'\n', u'\xa0\xa0', u'\n', u'$', u'\n', u'9,977', u'\n', u'\xa0\xa0', u'\n', u'$', u'\n', u'1,125', u'\n', u'\xa0', u'\n', u'\n', u' ', u'Marketable securities', u'\n', u'\xa0\xa0', u'\n', u'\xa0', u'\n', u'12,211', u'\n', u'\xa0\xa0', u'\n', u'\xa0', u'\n', u'\x97', u'\n', u'\xa0', u'\n', u'\n', u' ', u'Restricted cash', u'\n', u'\xa0\xa0', u'\n', u'\xa0', u'\n', u'\x97', u'\n', u'\xa0\xa0', u'\n', u'\xa0', u'\n', u'84', u'\n', u'\xa0', u'\n', u'\n', u' ', u'Accounts receivable', u'\n', u'\xa0\xa0', u'\n', u'\xa0', u'\n', u'133', u'\n', u'\xa0\xa0', u'\n', u'\xa0', u'\n', u'428', u'\n', u'\xa0', u'\n', u'\n', u' ', u'Other current assets', u'\n', u'\xa0\xa0', u'\n', u'\xa0', u'\n', u'268', u'\n', u'\xa0\xa0', u'\n', u'\xa0', u'\n', u'211', u'\n', u'\xa0', u'\n', u'\n', u'\xa0', u'\n', u'\xa0\xa0', u'\n', u'\n', u'\n', u'\xa0\xa0', u'\n', u'\n', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\xa0\xa0', u'\n', u'\xa0', u'\n', u'22,589', u'\n', u'\xa0\xa0', u'\n', u'\xa0', u'\n', u'1,848', u'\n', u'\xa0', u'\n', u'\n', u' ', u'Furniture, equipment and leasehold improvements, net', u'\n', u'\xa0\xa0', u'\n', u'\xa0', u'\n', u'269', u'\n', u'\xa0\xa0', u'\n', u'\xa0', u'\n', u'298', u'\n', u'\xa0', u'\n', u'\n', u' ', u'Other', u'\n', u'\xa0\xa0', u'\n', u'\xa0', u'\n', u'33', u'\n', u'\xa0\xa0', u'\n', u'\xa0', u'\n', u'33', u'\n', u'\xa0', u'\n', u'\n', u'\xa0', u'\n', u'\xa0\xa0', u'\n', u'\n', u'\n', u'\xa0\xa0', u'\n', u'\n', u'\n', u'\n', u'\n', u' ', u'Total assets', u'\n', u'\xa0\xa0', u'\n', u'$', u'\n', u'22,891', u'\n', u'\xa0\xa0', u'\n', u'$', u'\n', u'2,179', u'\n', u'\xa0', u'\n', u'\n', u'\xa0', u'\n', u'\xa0\xa0', u'\n', u'\n', u'\n', u'\xa0\xa0', u'\n', u'\n', u'\n', u'\n', u'\n', u' ', u'Liabilities and Stockholders\x92 Equity (Deficit):', u'\n', u'\xa0\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\n', u' ', u'Accounts payable and accrued expenses', u'\n', u'\xa0\xa0', u'\n', u'$', u'\n', u'1,815', u'\n', u'\xa0\xa0', u'\n', u'$', u'\n', u'1,335', u'\n', u'\xa0', u'\n', u'\n', u' ', u'Unearned revenue \x97 current', u'\n', u'\xa0\xa0', u'\n', u'\xa0', u'\n', u'206', u'\n', u'\xa0\xa0', u'\n', u'\xa0', u'\n', u'2,017', u'\n', u'\xa0', u'\n', u'\n', u' ', u'Unearned revenue \x97 non-current', u'\n', u'\xa0\xa0', u'\n', u'\xa0', u'\n', u'381', u'\n', u'\xa0\xa0', u'\n', u'\xa0', u'\n', u'247', u'\n', u'\xa0', u'\n', u'\n', u' ', u'Stockholders\x92 equity (deficit)', u'\n', u'\xa0\xa0', u'\n', u'\xa0', u'\n', u'20,489', u'\n', u'\xa0\xa0', u'\n', u'\xa0', u'\n', u'(1,420', u'\n', u')', u'\n', u'\n', u'\xa0', u'\n', u'\xa0\xa0', u'\n', u'\n', u'\n', u'\xa0\xa0', u'\n', u'\n', u'\n', u'\n', u'\n', u' ', u'Total liabilities and stockholders\x92 equity (deficit)', u'\n', u'\xa0\xa0', u'\n', u'$', u'\n', u'22,891', u'\n', u'\xa0\xa0', u'\n', u'$', u'\n', u'2,179', u'\n', u'\xa0', u'\n', u'\n', u'\xa0', u'\n', u'\xa0\xa0', u'\n', u'\n', u'\n', u'\xa0\xa0', u'\n', u'\n', u'\n', u'\n', u' ', u'\xa0', u' ', u'\xa0', u' ', u'More information at ', u'www.cortexpharm.com', u' ', u' ', u'\xa0', u' ', u'\xa0', u' ', u'\xa0', u' ', u'#\xa0\xa0\xa0\xa0#\xa0\xa0\xa0\xa0#\xa0\xa0\xa0\xa0#\xa0\xa0\xa0\xa0# ', u'\n', u'\n', u'\n', u'\n', u'GRAPHIC\n', u'3\n', u'g59722img05.jpg\n', u'GRAPHIC\n', u'\nbegin 644 g59722img05.jpg\nM_]C_X``02D9)1@`!`@``9`!D``#_[``11\'5C:WD``0`$````9```_^X`#D%D\nM;V)E`&3``````?_;`(0``0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!\nM`0$!`0$!`0$!`0$!`0("`@("`@("`@("`P,#`P,#`P,#`P$!`0$!`0$"`0$"\nM`@(!`@(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#\nM`P,#`P,#`P,#_\\``$0@`8P!8`P$1``(1`0,1`?_$`)````$%`0$!`0``````\nM``````H`!P@)"P8%`@0!`0`````````````````````0```&`0,"`P,$"@H3\nM`0````$"`P0%!@*"G`"A(,3BW?J-I`5WAW+DA2I%3W$!WW``\'0=QS"[@\'JGN"K->', u'83S`(!TC`8/L[!6?_`/J![QW\\\nMXYC_`-GQW^FT%\\_IS>]?W$>=W:1QQF(=]7TH\nM]R1R@J8Y?*(^5`P;#U;A]K0:`N@6@6@6@#>]6+(9$B', u'UD9!9>,B9\\RK1DB@\\(\'G\'#H\\T>C;\nM?0"F7WNM8%RK=[1DK)O;=XTWR^W68>3UHM%E7N\\A(RLH_6.X', u"I(!$?9H#]['6J];X61KEJA(NQ0,NS=1\\G#S+%O\nM(1[YD]04:NVSEJZ342427;JF(8!#Q*8=!G4=[G@MA;LN\\F_TI\\:\\*..?(WB/\nMRH*,&.)", u'Y(I&`&/LAS_`#"FXFD7LS)2\nM2+3[0_6QDUA+&:/2`5\'H0\\BJFX%(OB?R]@]N@J-[Q3\'OB', u'+Q:>XS\nM"#14LAPUWA>*\\S*UBE2TS)2D#(0+48^(E6GQ,;%/&C]H_=N#V#R@1406*J!^GH$1#0#*=@/)/+\nM7+7?\\F;MS;J=AI6?Y#C/84)Z!L^-V^*99&$:$IZ-7D_3U;557)6=FKB\nM=A4QG%\'FJ^[.4Q&TO&E="LW.("!52%\'0"I=Z.?RQVY>;]NXI0QWUMRU\nMBJA+V3\'&', u'S$&\\?$,V=``%5:I]"FZGRC`_F0?3\nM[', u'"A[C)U*^)69G)BI`4"M,H(K2KL:@T;F1Z\nM5Q:@H#=L)%!44.`B%B_?,PW:WO9BY.XZH=X?,\'M!Q+6WA+#/J&>3', u'J*N%$6C*1)](4GK>.V^X@`AK)\\G1BO,GU$\nM>T#GZ>+CV.N-PI+V@2]', u'9[ZJ@=(GNX\nM&\\T>@!T&19H+#NV=G&I8!Y$IW6X9XY+\\>HX]:EXY"Z\\4J]4[-E5P[[;+Y92[C[`T&MUVD&;A3A%BRVCG[/\'(V/R&B^NT/>^2$%`UW*\nMC>.FGBRZ,#.QM=*#$GPG?RDS;F,8A0$1\\=`#]ZTG)3R5YDIM_E(]C?^G6\'Y7Q3H"`>Y8!1[=_-P#$(', u"QC;I(.T&IW0PYXZ33.J:%58LA'$>V3E;(JH", u"*1U-Q[S#FKC:9!)!5P=C`5Y\nM?&,I*NBI(D4.J9NR;'/TE`3#MX!H'", u"I#[3>7^'7*3%%)SZ]E+AD3`&5:5\nM5(XM/LB`R-BLU(F(F'9`LO&%23\\Z0=ID,8VP``CX_9T&6**9P\\1(&+", u'*(DK)\nM2J[E(`^(2"27D,VHJ&(H*Q.C0\']X7]11V)^/^-*;AW#F5(_\'N.*1$,H.MUB`\nMQU/QT=\'LVR2:0K*I-8D@+OG1RBJZ', u'#[L[;MUR%3=MSE#O(M"=;N2L5WC=$A%#D`HG*4`\'P#0,&V[\nM8O;9=E%1IPHXK.2@(;J-L/T)8H".^VYDHDP`([:#]!NUUVY#E,0_!_B^8IRB\nM4Q1PU1Q`Q3!L("\'PCQ`0\'0=[;N!G"R_5B@TFZ\\6,$VFGXL:/6&-ZO.8UJ\\C`\nM49G)+K.G[:KQ3F..RADGCAP', u'*K?/UKD;C2WYBF;KB"S,)R/;-HJ`D:8Z8`\nMM`V6!EI(CALIL)AZRAL(!N`6H8VYKTNY=S*M6$\')QKQ6.?M)!\\:+]V24:OT3HG\'J$H*%VWT\'3XT[C_"#,-SIN/L:\nM\\C*#;;?D-0Z5$A8U:3\\^V\'3CEI', u'.1;.]XM`[@/EAU)!U!OH/M[W\'^#$\nM?8;O5\'/)O&`6/&TT^KE^B$)5T\\>5*=C!7*_BIPC1DN#%ZU%JIUD.("`$$?8&\nM@=26Y7\\', u'F$57,7$Q$@JF5\'WU^@@T"&_N#H!\\^Q!:W%AXW\\_KG$N75FRD\\[B?*EQ:UWI1\']N\nM91-#28-0*;GKB%IFHMZXGE5.M4\'[1M\')-P3-T@FFD4`#[(AX410H&J]Q+(,]1:Y7$(\nM.W\\;H&5S', u"7\nM[%-K+2/FBT1;*'3\\OK^+[W9ES", u'ROE#*;%QF/!!:[9.37()FM[M*YAXDNSE+2D*PF14%VF3L@Q2[4)U8\nMBAS1ATU"\'(853&*!(-.IU7Q]5H&DTJ#CZU4ZO%M(6OP$4@#>.B8MBD5%HR:(\nM@(]"**10`-Q$1]HB(Z#I1#B+*[[7\'A\\(Y,J[K%]TEYE!L@]GTX]Q\'RWP]W)E9E\\WW99%/S\nM`\'[F4V^@?*MY+XY8IR7`8OITTEU.8J[', u'`,P]P^)RU%W.J.;)RSFIVN&?T^4%C/0CL)?R9B$>E(9\nM.2CPW`#JE^20P@`^W06#9@Y66V?X^C;^+./+E==F&+0\nM^S95>0DD[*UF,KY4?BM(7&J905*059G%^0\'*QTE(DZA$VIB-S)G("9@.$W.$\nMW)N4Y5X*@LB6W%]QPGDN/=O:IE+$]ZC\',=-TR]P0IMYQ@W.Y20"7@E5S=;-\\\nMF4$G*0[E^:.@ESH([', u'C?;QWT%LN@J@Y%?"_TFZY_$I](^AI\\*^@?TP_2$\\GXJEYWQK?^"OW/??K\nM^,_?\'E;^5]C06G1\'7\\,8^9T^9[LCU]/D;]?0\'5YGNOWMYW5\\_P`O[GU;]/AM\nMH.!F_P`.5_BP]JGX[_#OGC^Z_L_X7[.@[2O_`(L;_B3_`#O_`$_^+/W3_5_\\\n>O_&T\'MZ#R8[\\*E/Q3^%_\\._"OF!^-/\\`:_[V@__9\n`\nend\n\n', u'\n', u'\n', u'\n-----END PRIVACY-ENHANCED MESSAGE-----\n']